Qualified institutional buyers were at the forefront of bidding and subscribed 92.94 times their allotted quota. On the other hand Non-Institutional investors took 42.57 times.The employees of the drugmaker placed bids of 7.9 times which were allotted to them and the retail investors took 6.33 times.Kotak Mahindra Capital Company Ltd, Axis Capital Ltd, J.P Morgan India Private Ltd, and Jefferies India Private ltd were the lead book running managers of the IPO.Emcure Pharmaceuticals founded in 1981 by Satish Mehta has come a long way. Initially it started out as manufacturing drugs for multinational pharma on contractual basis. Mehta finished his PG diploma from IIM-A and his passion drove him to the path of entrepreneurial journey of starting his drug manufacturing venture.The company today has expanded across India and it has 13 manufacturing units. It globally market a variety of dosage. The drugmaker does research and develops its own dosage with a product ranging from orals, injectables and biotherapeutics. The company has a market base in around 70 countries.
sekar nallalu Cryptocurrency,Markets Emcure Pharma, 43-Years Old Drugmaker Enters Dalal Street with 31% Premium
Related Posts
What is the Best Crypto for 2024 Bull Run? – Cryptocurrencies to Buy Now for 100X Gains – Disrupt Africa
Are you watching the crypto market, feeling that nagging fear that you might miss out on the next big rally?[...]
ITR Filing: All You Need to Know About New Changes Under New Tax Regime
ITR Filing: All You Need to Know About New Changes Under New Tax Regime Buy cryptocurrency Source link Refer And[...]
Secure a 50x Return with MOONHOP at Launch: An Early Opportunity Amidst Bonk Token Reduction & Positive Mpeppe Predictions
News surrounding BONK Coin has recently made headlines due to a 20% increase, spurred by a decisive token burn that[...]